Genomma Lab InternacionalB de CV (MEX:LABB) Piotroski F-Score: 4 (As of Jun. 26, 2026) — 33% Below Median


MEX:LABB Genomma Lab Internacional SAB de CV MEX:LABB
66 GF Score
Price MXN15.04
GF Value MXN17.64
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV Piotroski F-Score?

Genomma Lab InternacionalB de CV MEX:LABB +2.59% 66 Piotroski F-Score is 4 as of Jun. 26, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.64 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 981 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks worse than 61.06% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Genomma Lab InternacionalB de CV has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Genomma Lab InternacionalB de CV's Piotroski F-Score or its related term are showing as below:

MEX:LABB' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Genomma Lab InternacionalB de CV was 8. The lowest was 3. And the median was 6.

Genomma Lab InternacionalB de CV  (MEX:LABB) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Genomma Lab InternacionalB de CV Piotroski F-Score Related Terms


Genomma Lab InternacionalB de CV Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Genomma Lab InternacionalB de CV's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomma Lab InternacionalB de CV Piotroski F-Score Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 7.00 6.00 7.00 5.00

Genomma Lab InternacionalB de CV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 5.00 5.00 4.00

MEX:LABB vs ZTS, UTHR, VTRS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Piotroski F-Score falls into.


MEX:LABB
66GF Score
Genomma Lab Internacional SAB de CV MEX:LABB
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 354.966 + 434.066 + 319.636 + 494.647 = MXN1,603 Mil.
Cash Flow from Operations was 509.532 + 440.33 + 1255.694 + -229.167 = MXN1,976 Mil.
Revenue was 4676.435 + 4441.43 + 4016.967 + 4190.623 = MXN17,325 Mil.
Gross Profit was 2969.415 + 2836.157 + 2449.239 + 2657.588 = MXN10,912 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(24080.376 + 24244.526 + 23608.38 + 23690.512 + 24800.496) / 5 = MXN24084.858 Mil.
Total Assets at the begining of this year (Mar25) was MXN24,080 Mil.
Long-Term Debt & Capital Lease Obligation was MXN4,729 Mil.
Total Current Assets was MXN13,661 Mil.
Total Current Liabilities was MXN7,652 Mil.
Net Income was 631.645 + 660.06 + -170.689 + 498.719 = MXN1,620 Mil.

Revenue was 4651.495 + 5092.514 + 4665.574 + 4406.326 = MXN18,816 Mil.
Gross Profit was 2977.7 + 3272.001 + 2941.672 + 2767.321 = MXN11,959 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(21311.788 + 21984.814 + 23508.259 + 23017.803 + 24080.376) / 5 = MXN22780.608 Mil.
Total Assets at the begining of last year (Mar24) was MXN21,312 Mil.
Long-Term Debt & Capital Lease Obligation was MXN3,998 Mil.
Total Current Assets was MXN13,053 Mil.
Total Current Liabilities was MXN8,393 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Genomma Lab InternacionalB de CV's current Net Income (TTM) was 1,603. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Genomma Lab InternacionalB de CV's current Cash Flow from Operations (TTM) was 1,976. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=1603.315/24080.376
=0.06658181

ROA (Last Year)=Net Income/Total Assets (Mar24)
=1619.735/21311.788
=0.07600184

Genomma Lab InternacionalB de CV's return on assets of this year was 0.06658181. Genomma Lab InternacionalB de CV's return on assets of last year was 0.07600184. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Genomma Lab InternacionalB de CV's current Net Income (TTM) was 1,603. Genomma Lab InternacionalB de CV's current Cash Flow from Operations (TTM) was 1,976. ==> 1,976 > 1,603 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=4728.675/24084.858
=0.19633394

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=3998.252/22780.608
=0.17551121

Genomma Lab InternacionalB de CV's gearing of this year was 0.19633394. Genomma Lab InternacionalB de CV's gearing of last year was 0.17551121. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=13661.115/7652.101
=1.78527636

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=13053.358/8392.563
=1.55534823

Genomma Lab InternacionalB de CV's current ratio of this year was 1.78527636. Genomma Lab InternacionalB de CV's current ratio of last year was 1.55534823. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Genomma Lab InternacionalB de CV's number of shares in issue this year was 977.753. Genomma Lab InternacionalB de CV's number of shares in issue last year was 973.793. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=10912.399/17325.455
=0.62984776

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=11958.694/18815.909
=0.63556292

Genomma Lab InternacionalB de CV's gross margin of this year was 0.62984776. Genomma Lab InternacionalB de CV's gross margin of last year was 0.63556292. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=17325.455/24080.376
=0.71948441

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=18815.909/21311.788
=0.8828874

Genomma Lab InternacionalB de CV's asset turnover of this year was 0.71948441. Genomma Lab InternacionalB de CV's asset turnover of last year was 0.8828874. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Genomma Lab InternacionalB de CV has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Piotroski F-Score of 4 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Genomma Lab InternacionalB de CV's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #599 out of 981 companies in the Drug Manufacturers industry, placing it in the top 61.1%.
Is Genomma Lab InternacionalB de CV's Piotroski F-Score too high?
Genomma Lab InternacionalB de CV's current Piotroski F-Score of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Genomma Lab InternacionalB de CV's value of 4 is 20% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #599 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #599 out of 981 companies for Piotroski F-Score. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Genomma Lab InternacionalB de CV's value of 4 is 20% below this benchmark. Historically, Genomma Lab InternacionalB de CV's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Genomma Lab InternacionalB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Piotroski F-Score is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current Piotroski F-Score is 4, which is 33% below median its 10-year median of 6.00 and 20% below the Drug Manufacturers industry median of 5.00. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Piotroski F-Score is 4 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64. GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.

Key valuation signals for MEX:LABB:

  • Piotroski F-Score: 4 (33% below median its 10-year median of 6.00)
  • GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
  • GF Score™: 66/100 with 4 warning signs
  • Industry Position: 20% below the Drug Manufacturers median (#599 of 981)

No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genomma Lab InternacionalB de CV Business Description

Other Exchanges GNMLF:USAGEKA:Germany
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score

Get the complete analysis for MEX:LABB

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN15.04
Price
MXN17.64
GF Value